Following intratumoral injection of Type 1-polarized DC (DC engineered to overexpress Tbet, i.e., DC.Tbet) into established murine sarcomas or colon carcinomas, CD4+ and CD8+ T cell recruitment to the TME is observed within 2 days, with an upregulation of PNAd expression detected by 5 days after treatment. The gene discussed is TBX21; the disease is sarcoma.